Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) (ConCoVid-19)

Erasmus University

Status and phase

Terminated

Phase 3

Phase 2

Conditions

COVID-19

Treatments

Biological: Convalescent plasma

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT04342182

NL73489.078.20

Details and patient eligibility

About

Passive immunization with immunoglobulins is occasionally used as therapy for the treatment of viral infectious diseases. Immunoglobulins are used for the treatment of CMV disease, and is effective as prophylaxis when given soon after exposure to varicella zoster virus, rabies, and hepatitis B virus.

Neutralizing antibodies against MERS, SARS-CoV-1 and SARS-CoV-2 have been shown to be present in patients previously infected with MERS, SARS-CoV-1 and SARS-CoV-2 respectively. During the 2003 SARS outbreak in Hong-Kong,a non-randomized study in hospitalized SARS patients showed that treatment with convalescent plasma (convP) from SARS-recovered donors significantly increased the day 22 discharge rate and decreased mortality. A study in non-human primates showed that rhesus macaques could not be re-infected with SARS-CoV-2 after primary infection.

With no proven effective therapy against COVID, this study will evaluate the safety and efficacy of convalescent plasma from COVID-recovered donors as a treatment for hospitalized patients with symptomatic COVID-19. The study will focus on patients who tested positive for SARS-CoV-2 in the last 96 hours before inclusion

Primary objectives

• Decrease overall mortality in patients within COVID disease

Study design:

This trial is a randomized comparative trial. Patients will be randomized between the infusion of 300mL of convP with standard of care.

Patient population:

Patients with PCR confirmed COVID disease, age >18 years Donors will be included with a known history of COVID who have been asymptomatic for at least 14 days.

Intervention: 300mL of convP Duration of treatment: ConvP will be given as a one-time infusion Duration of follow up: For the primary endpoint: until discharge or death before day 60, whichever comes first. For the secondary endpoints (with separate consent) up to 1 year.

Target number of patients: 426 Target number of donors: 100 Expected duration of accrural: 36 months

Full description

Secondary (exploratory) objectives

Evaluate the effect of 300ml convP on hospital stay
Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 and 30
Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80
Evaluate the effect of 300ml convP on mortality in patients admitted to the ICU
Evaluate the effect of 300ml plasma therapy on hospital days for patients admitted to the ICU within 24 hours after admission
Evaluate the impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways
Evaluate the difference in effect of convP on mortality in patients with a duration of symptoms < or > the median duration of symptoms in the study population
Evaluate the impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer
Safety of convP therapy
Evaluate the impact of covP on long-term lung function

Enrollment

86 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with PCR confirmed COVID disease
Admitted to the hospital
The most recent PCR positive sample is <96hrs old
Written informed consent by patient or legal patient representative
Age at least 18 years

Exclusion criteria

Participation in another intervention trial on the treatment of COVID-19 that falls under the Dutch law human research (WMO) and in which individual patients are randomized to different treatment options
Known IgA deficiency
Invasive ventilation for already >96 hours

Donors: Eligibility for plasma donation

Inclusions Criteria:

A history of COVID infection that was documented by PCR
Known ABO-Resus(D) blood group
A screening for irregular antibodies with a titer ≤ 1:32
Asymptomatic for at least 14 days
Written informed consent regarding the plasmapheresis procedure
Tested negative for HIV, HBV, HCV, HEV, HTLV and syfilis

Exclusion Criteria:

Age <18 years and > 65 years
Weight <50kg
Medical history of heart failure
History of transfusion with red blood cells, platelets or plasma
History of organ- or tissue transplant
A cumulative stay in the United Kingdom of ≥ 6 months in the period between 01-01-1980 and 31-12-1996
A history of i.v. drug use
Insulin dependent diabetes
An underlying severe chronic illness (i.e. history of heart failure, cancer or stroke)
Tested positive for HLA- or HNA-antibodies